$bluebird bio (BLUE.US)$ bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition Positive 94.7% of evaluable patients achieved complete resolution of severe VOEs 86.8% of evaluable patients achieved complete resolution of VOEs 100% success rate in pediatric patients (10/10) for VOE resolution No stroke recurrence in patients with prior history through 9 y...
$bluebird bio (BLUE.US)$Bluebird Bio Announced Long-Term Follow-Up Data Continue To Support Beti-Cel As Potentially Curative Gene Therapy For Β-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable Transfusion Independence And Normal Or Near-Normal Adult Hb Levels At ASH Meeting bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
$bluebird bio (BLUE.US)$ bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition Sunday, 8th December at 12:30 pm Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially trans...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Positive
94.7% of evaluable patients achieved complete resolution of severe VOEs
86.8% of evaluable patients achieved complete resolution of VOEs
100% success rate in pediatric patients (10/10) for VOE resolution
No stroke recurrence in patients with prior history through 9 y...
bluebird bio, Inc. (NASDAQ:BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with be...
bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Sunday, 8th December at 12:30 pm
Stable production of anti-sickling adult hemoglobin (HBAT87Q) and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients (n=38), underscoring potentially trans...
At the moment, the Wall Street is partying like it’s 1998 as market optimism fuels gains unmatched since the 2000 dot-com bubble.
This bullish market momentum is so strong to a point where it seems like nothing will disrupt it. Well, is that really the case?
$Salesforce (CRM.US)$ $CrowdStrike (CRWD.US)$ $Nike (NKE.US)$ $Taiwan Semiconductor (TSM.US)$ $Advanced Micro Devices (AMD.US)$ $Johnson & Johnson (JNJ.US)$ $Disney (DIS.US)$ $Sea (SE.US)$ $Grab Holdings (GRAB.US)$ $iShares Bitcoin Trust (IBIT.US)$ $Intel (INTC.US)$